ARS Pharmaceuticals Faces Class Action Lawsuit Over Misleading Statements
News related to:ARS Pharmaceuticals, Inc · 2 min read
LOS ANGELES, Sept. 8, 2026 /CourierPR/ -- ARS Pharmaceuticals, Inc. faces a class action lawsuit filed by Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, on behalf of investors who purchased shares of the company during a specific period. The lawsuit alleges that ARS made false and misleading statements to the market, failing to disclose critical risks related to CVS Caremark's addition of neffy to its formulary.
According to the complaint, ARS knew or recklessly disregarded the timeline problems that could arise due to CVS Caremark’s addition of neffy to its formulary. The company's guidance on the timeline for insurance coverage for neffy was later revealed to be false and materially misleading, significantly impacting the company's commercialization efforts. When the truth about ARS was finally disclosed to the market, investors suffered substantial losses.
Schall, Brown & Schwartz LLP is reminding investors who purchased SPRY shares between March 9, 2026, and June 24, 2026, of their right to participate in the lawsuit. The firm encourages shareholders who believe they may have suffered a loss to contact them to discuss their options. The deadline for appointing a lead plaintiff is October 5, 2026. Participation in the case is not required to partake in any recovery, but investors are encouraged to act promptly.
The lawsuit is based on violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. ARS is accused of making false and misleading statements that misled investors about the timeline for insurance coverage of neffy, a drug the company was developing. The lawsuit claims that the company's statements throughout the class period were false and materially misleading.
Schall, Brown & Schwartz LLP is known for representing investors in securities class action lawsuits and shareholder rights litigation. The firm has a team of experienced lawyers, including founding partners Brian Schall, Andrew Brown, and David Schwartz, who are dedicated to aggressively advocating for every investor.